Ordaos Bio stands at the forefront of intelligent drug design, employing a sophisticated AI engine comprising hundreds of specialized digital models to conceive and engineer novel mini-proteins and single-domain antibodies from scratch. This de novo design capability is coupled with an unprecedented 5-day wet-lab validation cycle, utilizing a proprietary high-yield cell-free expression system. This rapid iteration between computational design and experimental testing allows for multi-objective optimization from the outset, predicting binding, stability, function, and safety in silico. The company has demonstrated significant success, delivering functional molecules for Tier-1 pharmaceutical partners on challenging targets such as cytokine receptor agonism for IBD. Ordaos' platform consistently achieves high hit rates, drastically reducing traditional discovery timelines and costs. Ordaos is not just applying AI to biology; it is engineering the medicines of tomorrow.